SecBot SecBot

AVXL

ANAVEX LIFE SCIENCES CORP.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001314052 Biotech & Drug Discovery
$1.28 −0.05 (−3.76%)
Oct 26 4:00 PM ET · prev $1.33
Market cap
$126.1M
Micro cap
Median target
$20.00
+1463% · range $20.00–20.00
Next earnings
Nov 23
in 28 days
1 year
−84.9%
from $8.49 · Oct 27
30 days
−45.5%
from $2.35
52-week range
$1.25–8.49
−85% from high · low Oct 19
Avg volume 20D
1.53M
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
29
analyzed by SecBot
SecBot read BULLISH 25 reports · 90 days
Balance 1 bearish · 5 bullish · 4 mixed · 15 neutral oldest → newest, height = score
Avg score ·High conf. 19/25 ·Next Earnings date, Nov 23, 2026
Strongest BULLISH Activist investor PVG Asset Management, holding 337,663 shares of Anavex, announced that proxy advisor Glass…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 21 added (0 new), 15 trimmed or exited.

  • TrendDOWNTREND

    44% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPTRIM1,922,770$5.0M
FEDERATED HERMES, INC.DOUBLED1,071,809$2.8M
MARSHALL WACE, LLPDOUBLED889,523$2.3M
BARCLAYS PLCADD754,226$2.0M
STIFEL FINANCIAL CORPADD332,597$861.4K
CITADEL ADVISORS LLCTRIM329,115$852.4K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM319,529$827.6K
CANADA PENSION PLAN INVESTMENT BOARDADD201,800$522.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +1463%.Targets as of Sep 29, 2026.

Recent actions
DateFirmActionRating
Mar 31, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Mar 26, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Mar 23, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Feb 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Feb 9, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Jan 6, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 24, 2026
Boenisch Sandra
PFO & Treasurer
AWARD20,000 sh
Sep 24, 2026
Boenisch Sandra
PFO & Treasurer
AWARD25,000 sh

Earnings setup

Estimates
Nov 23
reports in 28 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 23, 2026
Earnings date
AVXL Q4 2026 Earnings After Market Close — 2026-11-23
Recent
Oct 20, 2026
FDA
Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical…
Oct 20, 2026
Press release
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life…
Oct 15, 2026
FDA
Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the...
Oct 15, 2026
Press release
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life…
Oct 5, 2026
Press release
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Oct. 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on…

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Anavex announced completion of clinical conduct for two blarcamesine pharmacology studies (ADME and DDI) in healthy…
8-K — Impact 4/10
Oct 20, 2026 Press
Anavex provided a corporate update on blarcamesine across three CNS indications. Clinical conduct was completed for…
Impact 3/10
Oct 20, 2026 FDA
Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, d
Oct 15, 2026 SEC
Anavex received FDA clearance to proceed with its IND for blarcamesine in Fragile X syndrome, enabling a Phase 2a…
8-K — Impact 4/10
Oct 15, 2026 Press
Anavex received FDA clearance to proceed with its IND for blarcamesine (ANAVEX®2-73) in Fragile X syndrome, enabling a…
Impact 4/10
Sep 28, 2026 SEC
Anavex Life Sciences held its 2026 Annual Meeting on September 24, 2026, where all six management director nominees…
8-K — Impact 5/10
Sep 24, 2026 Insider
Boenisch Sandra was granted 20,000 shares
PFO & Treasurer
Sep 24, 2026 Insider
Boenisch Sandra was granted 25,000 shares
PFO & Treasurer

Washington

Q3 2026
Lobbying Q3 None no reports
YoY n/a vs Q3 2025
Members 0 all time
Buys / sells 0 / 0 0 trades
Open in Washington ›

SecBot reports

29 filings · 6 press releases · 5 bullish · 4 bearish · 4 mixed · 16 neutral
All AVXL filing & press-release reports (35)